Info@ThinkPinkRocks.com

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Oncolytics Biotech Inc. (“Oncolytics”) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency (“EMA”) for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

Continued here:
Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Share

Leave a Reply